Business Context and Reporting Period
Capstone Therapeutics Corp. (the filing entity identified in the source, although the request metadata names Capstone Holding Corp.) filed this unaudited Form 10-Q for the quarter and nine months ended September 30, 2018. The company operates primarily through its approximately 60%-owned joint venture, LipimetiX Development, Inc., which is developing AEM-28 and related Apo E mimetic peptides. The company uses a virtual operating model and has no commercial product revenue-generating operations.
Financial Highlights
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Sublicense revenue | $0 | $2.0 million |
| Total operating expenses | $633,000 | $1.823 million |
| Net income (loss) | $(693,000) | $(2,000) |
| Net income (loss) per share | $(0.01) | Approximately $0.00 |
| Cash flow from operating activities | Not separately reported | $541,000 provided |
- Third-quarter research and development expense was $507,000, compared with $386,000 in the prior-year quarter. General and administrative expense was $126,000, compared with $159,000.
- Nine-month research and development expense was $1.130 million, compared with $765,000, while general and administrative expense was $439,000, compared with $374,000.
- Interest and other expense was $60,000 in the third quarter and $182,000 for the nine-month period.
- Cash and cash equivalents were $1.816 million at September 30, 2018, including $1.506 million held by the joint venture. Total current liabilities were $417,000, versus $199,000 at December 31, 2017.
- Secured debt and accrued interest, net of unamortized issuance costs, was $2.415 million, compared with $2.249 million at year-end 2017. The underlying secured loan principal is $2.428 million, bears interest at 6%, and matures October 15, 2020.
- Total assets were $1.962 million and total equity was a deficit of $870,000 at September 30, 2018.
Material Changes Versus the Prior Comparable Period
- The joint venture entered into a sublicense with Anji Pharmaceuticals in May 2018 covering China, Taiwan and Hong Kong. The agreement generated a $2.0 million nonrefundable upfront payment, recognized as revenue in the second quarter. Related transaction costs were $254,000, resulting in approximately $1.746 million of net proceeds.
- The nine-month net loss improved to $2,000 from $1.191 million, primarily because of the sublicense revenue. The third-quarter net loss increased to $693,000 from $598,000 because operating expenses, particularly research and development, increased.
- Operating cash flow changed to $541,000 provided from $1.133 million used in the prior-year nine-month period, principally reflecting the sublicense-related economics, noncash items and increased accounts payable.
- On January 30, 2018, the company deferred secured-debt interest payments until maturity and issued Brookstone a warrant for up to 6,321,930 shares at an exercise price of $0.075 per share. Approximately 1,947,321 warrant shares were vested and exercisable at September 30, 2018.
- Shares outstanding increased from the prior-year weighted average levels; 54,385,411 common shares were outstanding as of November 1, 2018.
Guidance, Outlook, Risks and Unusual Items
- No quantitative financial guidance was provided. Management stated that additional funding is required to continue operations and advance AEM-28 development.
- Development activities remain materially limited because the company and joint venture do not currently have sufficient funding for additional material development. Management is pursuing fundraising, partnering, licensing or strategic transactions.
- Management states that the 2017 financing and related investor funding commitment alleviated substantial doubt regarding going-concern status, but additional funding will still be required to reach development goals and continue planned operations.
- The joint venture’s losses exceeded its capital accounts. The company has a revolving loan to the joint venture with a balance, including accrued interest, of approximately $1.7 million at September 30, 2018. The loan is generally due July 15, 2020, subject to earlier repayment in specified circumstances.
- If the joint venture cannot continue as a going concern, the company could recognize an additional $667,000 related to losses allocated to noncontrolling interests.
- Key risks include failure to obtain financing, unfavorable preclinical or clinical results, regulatory delays or failure, competition, loss or impairment of intellectual-property rights, dependence on the joint venture and partners, OTCQB listing risk, and failure to execute the AEM-28 development strategy.
- Patent license rights declined to $78,000 from $196,000 at year-end 2017, reflecting amortization. The filing identifies valuation of these rights as a significant accounting estimate.
- No legal proceedings were reported as of the filing date, and management stated that it did not believe a material loss contingency was reasonably possible, although legal outcomes remain uncertain.
Investor Verification Items
- Verify the terms, collectability and remaining obligations associated with the Anji sublicense, including future royalties and milestone payments.
- Assess whether the $1.816 million cash balance, particularly the $1.506 million held by the joint venture, is sufficient for near-term operations and debt obligations.
- Review the secured loan, accrued interest, maturity terms, collateral package and Brookstone-related warrant dilution.
- Determine the timing, amount and terms of any additional financing needed for AEM-28 development and continued operations.
- Evaluate the joint venture’s clinical, regulatory and intellectual-property status, including the impact of patent expirations currently estimated between 2019 and 2035.
- Reconcile the reported sublicense revenue, transaction costs, joint-venture loss allocations and the company’s continuing deficit equity position.